Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study

Overview of attention for article published in Frontiers in Neurology, August 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 18 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 11,854 followers.

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study https://t.co/edKzon28K6

24 Aug 2021

Reply Repost Favourite

New article: Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study https://t.co/2XxKS1960k #MS #multiplesclerosis #neurology https://t.co/LKSqp7bhlN

23 Aug 2021

Reply Repost Favourite

New Research: Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study: The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects… https://t.c

05 Aug 2021

Reply Repost Favourite

https://t.co/0ySpCDtbpz. The baseline data of one of the largest Alemtuzumab real world cohorts: TREAT-MS #alemtuzumab #multiplesklerose #multiplesclerosis #realworlddata

05 Aug 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.